About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that
transform the lives of patients with serious diseases often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus
is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and
innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow
@JazzPharma on Twitter.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. The Companys lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich
Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the
tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for
the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of
spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.
Jazz Pharmaceuticals Media Contact:
Jacqueline Kirby,
Vice President, Corporate Affairs & Government Relations
Ireland +353 1 697
2141 U.S. +1 215 867 4910
Jazz Pharmaceuticals Investor
Contact:
Andrea N. Flynn, Ph.D., Vice President, Head, Investor Relations
Ireland +353 1 634 7887 U.S. +1 650 496
2717
GW Pharmaceuticals Media Contacts:
US; Kristen
Cardillo, Vice President, Corporate Communication
U.S. kcardillo@gwpharm.com +1 760 579 6628
UK: Ben Atwell, FTI Consulting
London
ben.atwell@fticonsulting.com +44 (0)20 3727 1000
GW Pharmaceuticals Investor Contact:
Scott Giacobello, Chief Financial Officer
U.S.
sgiacobello@gwpharm.com +1 (760) 795 2200
Forward Looking Statements
This communication contains forward-looking statements regarding Jazz Pharmaceuticals and GW Pharmaceuticals, including, but not limited to, statements related
to the proposed acquisition of GW Pharmaceuticals and the anticipated timing, results and benefits thereof, including the potential for Jazz Pharmaceuticals to accelerate its growth and neuroscience leadership, and for the acquisition to provide
long-term growth opportunities to create shareholder value; Jazz Pharmaceuticals expected financing for the transaction; and other statements that are not historical facts. You can generally identify forward-looking statements by the use of
forward-looking terminology such as anticipate, believe, continue, could, estimate, expect, explore, evaluate, intend, may,
might, plan, potential, predict, project, seek, should, or will, or the negative thereof or other variations thereon or comparable terminology. These
forward-looking statements are based on each of the companies current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties, many of